Four-factor prothrombin complex concentrate (4F-PCC, such as Kcentra or Balfaxar) is an intravenous blood product used to rapidly replace clotting factors and reverse bleeding.
It Contains coagulation factors: Factors II, VII, IX, and X (all four vitamin K–dependent clotting factors).
Regulatory Proteins: Natural anticoagulant proteins C and S.
Stabilizers: Small amounts of heparin, antithrombin III, and human albumin to prevent premature protein activation.
Common Indications Vitamin K Antagonist Reversal: FDA-approved for the urgent reversal of coumarin/warfarin-induced major bleeding or before emergency invasive procedures/surgery.
Sometimes utilized in critical care settings for trauma-induced coagulopathy, liver failure, cardiac surgery bleeding, or specific direct oral anticoagulant (DOAC) related hemorrhages-off label.
Key Advantages Over Fresh Frozen Plasma (FFP)
Faster Reversal: Normalizes the international normalized ratio (INR) much quicker (often within 30 minutes).
Smaller Volume: Administered in a compact volume (roughly 100 mL) compared to several liters of FFP, reducing the risk of fluid overload.
Fixed dose four factor effective prothrombin complex concentrate regiments are typically dosed between 750 and 3000 IU depending on the site of bleeding.
No Cross-Matching: Does not require ABO blood typing or compatibility testing.
Important Risks & Warnings
Thromboembolic Complications: Carries a boxed warning for arterial and venous blood clots (such as stroke, deep vein thrombosis, or pulmonary embolism), especially in patients with a history of vascular disease.
Generally avoided or used with high caution in patients with a recent history of thrombosis, myocardial infarction, or disseminated intravascular coagulation (DIC) within the prior 3 months.
INR is the standard assay after prothrombin complex concentration infusion.
The evidence for the use of four factor prothrombin in patients on DOACs has limited evidence and appropriate dosing is undefined: the administration of factor four prothrombin complex aims to provide substrates for coagulation and not specific pharmacodynamic features of a DOAC.
The four factor prothrombin complex concentrate is widely available and less expensive than other agents, and is commonly used for factor 10a inhibitor associated major bleeding or perioperative reversal, given the lack of approved agent for factor Xa inhibitors.
Its main use is for urgent reversal of warfarin (vitamin K antagonist) in patients with acute major bleeding or who need emergency surgery.
It’s given alongside IV vitamin K, since PCC’s effect is short-lived. It is also used off-label for reversing factor Xa inhibitors (apixaban, rivaroxaban) when andexanet isn’t available.
Dosing is based on baseline INR and body weight (with a max dose cap), so follow the current product label or your institution’s protocol.
It works fast -minutes and needs no thawing or ABO matching, unlike plasma.
Main risk: thromboembolic events (stroke, MI, DVT/PE).
Contraindications: known heparin-induced thrombocytopenia (HIT), and DIC or known hypersensitivity to components.
Recheck INR after administration, and monitor for rebleeding or thrombosis.